Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novo Ventures, Third Rock co-lead PanOptica’s $45mm Series B round

Executive Summary

Ophthalmic pharma PanOptica Inc. closed a $45mm Series B financing led by new investor Novo Ventures and returning backer Third Rock Ventures, and including existing shareholder SV Life Sciences. The new funding will support the entry of the company’s lead candidate PAN90806, an eye drop for wet AMD, into Phase I. PanOptica holds exclusive worldwide rights to the small-molecular VEGF inhibitor through a January 2011 deal with Astellas’ OSI Pharmaceuticals.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies